$150M Stock Offering Priced by Mineralys Therapeutics
Summary
Mineralys Therapeutics has priced a $150 million underwritten offering of common stock. This significant capital raise, representing over 6% of its market cap, follows the FDA's acceptance of its New Drug Application for lorundrostat in March and its Q1 2026 financial results in May, which reported a robust cash position of $646.1 million. The additional funding will substantially strengthen the company's balance sheet, likely supporting the potential commercialization of lorundrostat and ongoing operations, though it will be dilutive to existing shareholders.
At the time of this announcement, MLYS was trading at $28.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $12.59 to $47.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.